Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02273817
Recruitment Status : Completed
First Posted : October 24, 2014
Last Update Posted : October 24, 2014
Sponsor:
Information provided by (Responsible Party):
Apotex Inc.

Brief Summary:
This study is to evaluate the equivalence of generic ciclesonide nasal spray with that of the marketed drug, Omnaris™ nasal spray, in the treatment of seasonal allergic rhinitis, and to evaluate the safety and tolerability of generic ciclesonide nasal spray compared with Omnaris™ nasal spray.

Condition or disease Intervention/treatment Phase
Seasonal Allergic Rhinitis Drug: Ciclesonide nasal spray, 50 μg per actuation. Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 580 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Comparing the Bioquivalence of Ciclesonide Nasal Spray(Apotex Inc.) to That of Omnaris ™Nasal Spray (Sepracor, Inc.) in the Treatment of Seasonal Allergic Rhinitis
Study Start Date : March 2011
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hay Fever
Drug Information available for: Ciclesonide

Arm Intervention/treatment
Experimental: Ciclesonide Nasal Spray (Apotex, Inc.)

Ciclesonide nasal spray

  • Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.
  • Strength: 50 μg per actuation.
  • Batch/Lot number (Expiry date): JM6697 (May 2012)
  • Manufacturer: Apotex, Inc.
Drug: Ciclesonide nasal spray, 50 μg per actuation.

During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.

During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:

  1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
  2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
  3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.

Active Comparator: Omnaris™ nasal spray

Omnaris™ Nasal Spray,

  • Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide
  • Strength: 50 μg per actuation
  • Batch/Lot number (Expiry date): 131657 (03/2012)
  • Manufacturer: Sepracor, Inc.
Drug: Ciclesonide nasal spray, 50 μg per actuation.

During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.

During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:

  1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
  2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
  3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.

Placebo Comparator: Placebo

Placebo

  • Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.
  • Batch/Lot number (Expiry date): JR3808 (Nov 2012)
  • Manufacturer: Apotex, Inc.
Drug: Ciclesonide nasal spray, 50 μg per actuation.

During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.

During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:

  1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
  2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
  3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.




Primary Outcome Measures :
  1. Treatment Of Seasonal Allergic Rhinitis [ Time Frame: 5 months ]
    Change from baseline in the combined reflective Total nasal symptom score (TNSS) (combined AM and PM reflective scores of runny nose, nasal congestion, nasal itchiness, and sneezing).


Secondary Outcome Measures :
  1. Treatment Of Seasonal Allergic Rhinitis [ Time Frame: 5 months ]
    Change from baseline in the combined AM and PM instantaneous scores of runny nose, nasal congestion, nasal itchiness, and sneezing.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • If female of childbearing potential, is not pregnant (confirmed by negative urine pregnancy test) or lactating and must have used reliable birth control measures throughout the study.
  • At least a 2-year reliable medical history consistent with SAR
  • Positive skin test within 12 months of screening to at least one seasonal allergen present in the geographical area
  • Capable of tolerating intranasal application of the IMP, willing and able to comply with the requirements of the protocol
  • No clinically significant findings in physical and nasal examinations, and medical history.
  • A reflective TNSS of at least 6 (out of 12) in the 24 hours prior to placebo lead-in visit.
  • Successfully complete the placebo lead-in period.

Exclusion Criteria:

  • - Signs or symptoms of nasal polyps, deviated septum, or any other condition which, in the opinion of the Investigator, could resulted in erroneous study data.
  • Undergo nasal surgery or had nasal trauma within 3 months of screening.
  • Active respiratory conditions or respiratory tract infection that require antibiotic treatment within 2 weeks of screening
  • Persistent allergic rhinitis (PAR) that does not require or not expected to require active PAR treatment during the study period.
  • Evidence of any unstable or clinically significant conditions that would place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives.
  • Presence or history of clinically significant conditions which in the opinion of the Investigator would have compromised the safety of the subject or the conduct of the study.
  • Use of corticosteroids, intranasal cromolyn, Leukotriene inhibitors, long or short acting antihistamines, intranasal or systemic decongestants prior to the start of the single-blind, placebo lead-in visit within the time periods specified in the protocol or receiving immunotherapy.
  • Use of an investigational drug within 30 days before screening or during the study.
  • Known or suspected hypersensitivity to corticosteroids.
  • Inability to avoid exposure to chicken pox or measles.
  • Infection requiring oral antibiotic treatment 2 weeks prior to screening.
  • Previously identified as a placebo responder or known as a non responder to corticosteroids.
  • History of alcohol, drug, or substance abuse in the 12 months prior to Visit 1 (screening).
  • Positive for hepatitis B or C, or human immunodeficiency virus (HIV).
  • Uncooperative or non compliant.
  • Female subjects who planned to become pregnant during the conduct of the study.
  • Current smoker (former smokers had to be 6 months smoke free).

Layout table for additonal information
Responsible Party: Apotex Inc.
ClinicalTrials.gov Identifier: NCT02273817    
Other Study ID Numbers: CICE-NASU-05SB03-CE
First Posted: October 24, 2014    Key Record Dates
Last Update Posted: October 24, 2014
Last Verified: February 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Ciclesonide
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents